OR WAIT null SECS
The Center for Breakthrough Medicines and BioAnalysis LLC have formed a strategic alliance to offer novel analytical testing services for CGT clients.
The Center for Breakthrough Medicines (CBM) announced on Feb. 23, 2022 that it has formed a strategic alliance with BioAnalysis LLC (BIA) to provide CBM’s clients with direct access to BIA’s advanced testing capabilities, including characterization of viral vectors using BIA’s proprietary sedimentation velocity approach to analytical ultracentrification, as well as other advanced biophysical methods and analytics.
CBM is a horizontally integrated cell and gene therapy (CGT) contract development and manufacturing organization (CDMO). Bioanalysis LLC is a non-clinical contract research organization (CRO) that specializes in biophysics and mass spectrometry applications for gene therapy, monoclonal antibodies, therapeutic proteins, antibody drug conjugates, and nanoparticles.
Through the alliance, CBM will gain scientific and data analysis from BIA founder and principal scientist, Dr. Lake Paul. The agreement will be a resource for CBM’s clients in need of assay and method development as well as a current good manufacturing practice compliant laboratory for characterization and advanced analytical methods.
"We could not be more delighted to partner with Dr. Paul and the BIA team—the next generation testing capabilities they bring to the table for CBM's innovator clients will be a game-changer," said Dana Cipriano, Senior Vice President of Testing and Analytical Services at Center for Breakthrough Medicines, in the press release.
"As a CDMO collaborator, BIA has found the perfect match in CBM," added Dr. Paul. "Our testing capabilities are unrivaled, and the sophisticated innovator clientele CBM connects with BIA will be a true differentiator in the CGT analytical testing space."